Advertisement

Personalized Treatment Strategies Effective in Hypertrophic Cardiomyopathy Do Not Rely on Genomics in 2022: A Different Tale of Precision Medicine

Published:September 14, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.07.033
      In his 2015 State of the Union Address, President Barack Obama launched a novel proposal for precision medicine
      • Collins FS
      • Varmus H.
      A new initiative on precision medicine.
      ,

      Congress.gov. S.3822 - genomics and personalized medicine act of 2006. Available at: https://www.congress.gov/bill/109th-congress/senate-bill/3822. Accessed on May 5, 2022.

      to treat, prevent, and cure chronic diseases, such as cancer,
      • Skoulidies F
      • Li BT
      • Dy GK
      • Price TJ
      • Falchook GS
      • Wolf J
      • Italiano A
      • Schuler M
      • Borghaei H
      • Barlesi F
      • Kato T
      • Curioni-Fontecedro A
      • Sacher A
      • Spira A
      • Ramalingam SS
      • Takahashi T
      • Besse B
      • Anderson A
      • Ang A
      • Tran Q
      • Mather O
      • Henary H
      • Ngarmchamnanrith G
      • Friberg G
      • Velcheti V
      • Govindan R.
      Sotorasib for lung cancers with KRASp.G12c mutation.
      • Mauro MJ
      • O'Dwyer ME
      • Druker BJ
      ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
      • Ross JS
      • Slodkowska EA
      • Symmans WF
      • Pusztai L
      • Ravdin PM
      • Hortobagyi GN.
      The HER-2 receptor and breast cancer: 10 years of targeted anti-HER-2 therapy and personalized medicine.
      • Dokmanovic M
      • Wu WJ.
      Monitoring trastuzumab resistance and cardiotoxicity: a tale of personalized medicine.
      cystic fibrosis,
      • Chang EH
      • Zabner J.
      Precision genomic medicine in cystic fibrosis.
      and chronic myelogenous leukemia,
      • Mauro MJ
      • O'Dwyer ME
      • Druker BJ
      ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
      employing strategies that account for patient variability and discard the traditional broad category “one-size-fits-all”. In principle, this personalized approach promotes targeted diagnosis and therapeutics by integrating information from multiple sources, including digital health analytics, proteomics, imaging, and genomics.
      • Weldy CS
      • Ashley EA.
      Towards precision medicine in heart failure.
      • Ashley EA.
      Toward precision medicine.
      • Ashley EA.
      The precision medicine initiative: a new national effort.
      • Dainis AM
      • Ashley EA.
      Cardiovascular precision medicine in the genomics era.
      • Ware JS
      • Roberts AM
      • Cook SA.
      Next generation sequencing for clinical diagnostics and personalized medicine: implications for the next generation cardiologist.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Collins FS
        • Varmus H.
        A new initiative on precision medicine.
        N Engl J Med. 2015; 372: 793-795
      1. Congress.gov. S.3822 - genomics and personalized medicine act of 2006. Available at: https://www.congress.gov/bill/109th-congress/senate-bill/3822. Accessed on May 5, 2022.

        • Skoulidies F
        • Li BT
        • Dy GK
        • Price TJ
        • Falchook GS
        • Wolf J
        • Italiano A
        • Schuler M
        • Borghaei H
        • Barlesi F
        • Kato T
        • Curioni-Fontecedro A
        • Sacher A
        • Spira A
        • Ramalingam SS
        • Takahashi T
        • Besse B
        • Anderson A
        • Ang A
        • Tran Q
        • Mather O
        • Henary H
        • Ngarmchamnanrith G
        • Friberg G
        • Velcheti V
        • Govindan R.
        Sotorasib for lung cancers with KRASp.G12c mutation.
        N Engl J Med. 2021; 384: 2371-2381
        • Mauro MJ
        • O'Dwyer ME
        • Druker BJ
        ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
        Cancer Chemother Pharmacol. 2001; 48: S77-S78
        • Ross JS
        • Slodkowska EA
        • Symmans WF
        • Pusztai L
        • Ravdin PM
        • Hortobagyi GN.
        The HER-2 receptor and breast cancer: 10 years of targeted anti-HER-2 therapy and personalized medicine.
        Oncologist. 2009; 14: 320-368
        • Dokmanovic M
        • Wu WJ.
        Monitoring trastuzumab resistance and cardiotoxicity: a tale of personalized medicine.
        Adv Clin Chem. 2015; 70: 95-130
        • Chang EH
        • Zabner J.
        Precision genomic medicine in cystic fibrosis.
        Clin Transl Sci. 2015; 8: 606-610
        • Weldy CS
        • Ashley EA.
        Towards precision medicine in heart failure.
        Nat Rev Cardiol. 2021; 18: 745-762
        • Ashley EA.
        Toward precision medicine.
        Nat Rev Genet. 2016; 17: 507-522
        • Ashley EA.
        The precision medicine initiative: a new national effort.
        JAMA. 2015; 313: 2119-2120
        • Dainis AM
        • Ashley EA.
        Cardiovascular precision medicine in the genomics era.
        JACC Basic Transl Sci. 2018; 3: 313-326
        • Ware JS
        • Roberts AM
        • Cook SA.
        Next generation sequencing for clinical diagnostics and personalized medicine: implications for the next generation cardiologist.
        Heart. 2012; 98: 276-281
        • Maron BA
        • Wang RS
        • Shevtsov S
        • Drakos SG
        • Arons E
        • Wever-Pinzon O
        • Huggin GS
        • Samokhin AO
        • Oldham WM
        • Aguib Y
        • Yacoub MH
        • Rowin EJ
        • Maron BJ
        • Maron MS
        • Lascalzo J.
        Individual for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical path phenotypes.
        Nat Commun. 2021; 12: 873-884
        • Maron BJ
        • Maron MS
        • Maron BA
        • Loscalzo J.
        Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy. JACC review topic of the week.
        J Am Coll Cardiol. 2019; 73: 1978-1986
        • Ingles J
        • Burns C
        • Bagnall RD
        • Lam L
        • Yeates L
        • Sarina T
        • Puranik R
        • Briffa T
        • Atherton JJ
        • Driscoll T
        • Semsarian C.
        Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications.
        Circ Cardiovasc Genet. 2017; e001620
        • Ingles J
        • Goldstein J
        • Thaxton C
        • Caleshu C
        • Corty EW
        • Crowley SB
        • Dougherty K
        • Harrison SM
        • McGlaughon J
        • Milko LV
        • Morales A
        • Seifert BA
        • Strande N
        • Thomson K
        • Peter van Tintelen J
        • Wallace K
        • Walsh R
        • Wells Q
        • Whiffin N
        • Witkowski L
        • Semsarian C
        • Ware JS
        • Hershberger RE
        • Funke B.
        Evaluating the clinical validity of hypertrophic cardiomyopathy genes.
        Circ Genom Precis Med. 2019; e002460
        • Maron BJ.
        Clinical course and management of hypertrophic cardiomyopathy.
        N Engl J Med. 2018; 379: 655-668
        • Maron BJ
        • Desai MY
        • Nishimura RA
        • Spirito P
        • Rakowski H
        • Towbin JA
        • Rowin EJ
        • Maron MS
        • Sherrid MV.
        Management of hypertrophic cardiomyopathy: JACC State-of-the-Art Review.
        J Am Coll Cardiol. 2022; 79: 390-414
        • Rowin EJ
        • Maron MS
        • Chan RH
        • Hausvater A
        • Wang W
        • Rastegar H
        • Maron BJ.
        Interaction of adverse disease-related pathways in hypertrophic cardiomyopathy.
        Am J Cardiol. 2017; 120: 2256-2264
        • Ommen SR
        • Mital S
        • Burke MA
        • Day SM
        • Deswal A
        • Elliott P
        • Evanovich LL
        • Hung J
        • Joglar JA
        • Kantor P
        • Kimmelstiel C
        • Kittleson M
        • Link MS
        • Maron MS
        • Martinez MW
        • Miyake CY
        • Schaff HV
        • Semsarian C
        • Sorajja P.
        2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2020; : e159-e240
        • Sherrid MV
        • Shetty A
        • Winson G
        • Kim B
        • Musat D
        • Alviar CL
        • Homel P
        • Balaram SK
        • Swistel DG.
        Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil.
        Circ Heart Fail. 2013; 6: 694-702
        • Sherrid MV
        • Barac I
        • McKenna WJ
        • Elliott PM
        • Dickie S
        • Chojnowska L
        • Casey S
        • Maron B.
        Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2005; 45: 1251-1258
        • Olivotto I
        • Oreziak A
        • Barriales-Villa Abraham TP
        • Masri A
        • Garcia-Pavia P
        • Saberi S
        • Lakdawala NK
        • Wheeler MT
        • Owens A
        • Kubanek M
        • Wojakowski W
        • Jensen MK
        • Gimeno-Blanes J
        • Afshar K
        • Myers J
        • Hegde SM
        • Solomon SD
        • Sehnert AJ
        • Zhang D
        • Li W
        • Bhattacharya M
        • Edelberg JM
        • Waldman CB
        • Lester SJ
        • Wang A
        • Ho CY
        • Jacoby D
        Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo controlled Phase 3 trial.
        Lancet. 2020; 396: 759-769
        • Maron BJ
        • Maron MS
        • Sherrid MV
        • Rowin EJ.
        Future role of new negative inotropic agents in the era of established surgical myectomy for symptomatic obstructive hypertrophic cardiomyopathy.
        J Am Heart Assoc. 2022; e024566
        • Maron MS
        • Ommen SR.
        Exploring new and old therapies for obstructive hypertrophic cardiomyopathy: mavacamten in perspective.
        Circulation. 2021; 143: 1181-1183
        • Maron BJ
        • Desai MY
        • Nishimura RA
        • Spirito P
        • Rakowski H
        • Towbin JA
        • Rowin EJ
        • Maron MS
        • Sherrid MV.
        Diagnosis and Evaluation of hypertrophic cardiomyopathy: JACC State-of-the-Art Review.
        J Am Coll Cardiol. 2022; 79: 372-389
        • Yeates L
        • McDonald K
        • Burns C
        • Semsarian C
        • Carter S
        • Ingles J.
        Decision-making and experiences of preimplantation genetic diagnosis in inherited heart diseases: a qualitative study.
        Eur J Hum Genet. 2022; 30: 187-193
        • Ma H
        • Marti-Gutierrez N
        • Park SW
        • Wu J
        • Lee Y
        • Suzuki K
        • Koski A
        • Ji D
        • Hayama T
        • Ahmed R
        • Darby H
        • Van Dyken C
        • Li Y
        • Kang E
        • Park AR
        • Kim D
        • Kim ST
        • Gong J
        • Gu Y
        • Xu X
        • Battaglia D
        • Krieg SA
        • Lee DM
        • Wu DH
        • Wolf DP
        • Heitner SB
        • Belmonte J
        • Amato P
        • Kim JS
        • Kaul S
        • Mitalipov S.
        Correction of a pathogenic gene mutation in human embryos.
        Nature. 2017; 548: 413-419